RecruitingNCT07329257

Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)

Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders


Sponsor

University of Missouri-Columbia

Enrollment

100 participants

Start Date

Dec 4, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Rare genetic neurodevelopmental disorders, such as Syt-1 or Baker Gordon Syndrome (BAGOS) arise from mutations in genes essential for brain development and function, often disrupting neurotransmission and neuronal connectivity. These conditions present with a wide range of symptoms including developmental delays, seizures, motor and behavioral challenges, and vary widely in severity. These disorders are complex, and they remain poorly understood and lack effective treatments. Natural history and clinical genetic studies are crucial for mapping how these disorders progress, improving diagnostic accuracy, and guiding therapy development. A major focus is identifying reliable biomarkers (genetic, imaging, and physiological) to track disease severity and support clinical trials. This study will securely collect and analyze data to better understand disease impact, develop patient-derived model systems, and build resources to support future treatments.


Eligibility

Max Age: 99 Years

Inclusion Criteria6

  • For those with a rare condition:
  • Diagnosed or suspected neurogenetic disorder
  • Individuals 0-99
  • No history of a neurological disorder.
  • >18 years.
  • Legal caregiver of the patient diagnosed with a rare neurodevelopmental disorder.

Exclusion Criteria10

  • Individuals unwilling or unable to complete visits with the study team.
  • For control parents/caregivers of those with a rare condition:
  • Individuals unwilling or unable to complete the visit with the study team.
  • Individuals who have a history of neurological disorders.
  • < 18 years old
  • For all individuals who participate in the skin biopsy:
  • Individuals with disease that is known to be associated with poor wound healing.
  • Individuals with a history of allergic reaction to lidocaine.
  • Medical History of cellulitis, diabetes mellitus, poor extremity circulation, deep vein thrombosis, or a history of non-traumatic amputation.
  • Currently taking anticoagulation or have taken with last 6 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention: Observational Cohort

There is no intervention for this Natural History Study


Locations(1)

University of Missouri - Columbia

Columbia, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07329257


Related Trials